+

US9452243B2 - Implant comprising an active-agent-containing coating covering the implant at least in sections - Google Patents

Implant comprising an active-agent-containing coating covering the implant at least in sections Download PDF

Info

Publication number
US9452243B2
US9452243B2 US13/306,238 US201113306238A US9452243B2 US 9452243 B2 US9452243 B2 US 9452243B2 US 201113306238 A US201113306238 A US 201113306238A US 9452243 B2 US9452243 B2 US 9452243B2
Authority
US
United States
Prior art keywords
implant
subsection
implant according
coating
subsections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/306,238
Other versions
US20120150284A1 (en
Inventor
Matthias Gratz
Alexander Borck
Alexander Rzany
Robert Schmiedl
Matthias Fringes
Claus Harder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotronik AG
Original Assignee
Biotronik AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotronik AG filed Critical Biotronik AG
Priority to US13/306,238 priority Critical patent/US9452243B2/en
Assigned to BIOTRONIK AG reassignment BIOTRONIK AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RZANY, ALEXANDER, DR., SCHMIEDL, ROBERT, DR., HARDER, CLAUS, DR., BORCK, ALEXANDER, DR., FRINGES, MATTHIAS, GRATZ, MATTHIAS, DR.
Publication of US20120150284A1 publication Critical patent/US20120150284A1/en
Application granted granted Critical
Publication of US9452243B2 publication Critical patent/US9452243B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body

Definitions

  • the invention relates to an implant comprising an active-agent-containing coating which covers the implant at least in sections.
  • Implants are utilized in modern medical technology in a variety of embodiments. They are used e.g. to support vessels, hollow organs, and ductal systems (endovascular implants e.g. stents), to attach and temporarily fix tissue implants and tissue transplants in position, and for orthopedic purposes such as pins, plates, or screws.
  • endovascular implants e.g. stents
  • the stent is a form of an implant that is used particularly frequently.
  • Stent implantation has become established as one of the most effective therapeutic measures for treating vascular disease.
  • Stents are used to provide support in a patient's hollow organs.
  • stents of a conventional design have a filigree support structure composed of metallic struts; the support structure is initially provided in a compressed form for insertion into the body, and is expanded at the application site.
  • One of the main applications of stents of this type is to permanently or temporarily widen and hold open vasoconstrictions, in particular constrictions (stenoses) of the coronary arteries.
  • aneurysm stents are known, for example, which are used primarily to seal the aneuryism. They also perform the support function.
  • Stents include a circumferential wall having a support force that suffices to hold the constricted vessel open to the desired extent; stents also include a tubular base body through which blood continues to flow without restriction.
  • the circumferential wall is typically formed by a latticed support structure that enables the stent to be inserted, in a compressed state having a small outer diameter, until it reaches the constriction in the particular vessel to be treated, and to be expanded there, e.g. using a balloon catheter, until the vessel finally has the desired, enlarged inner diameter.
  • materials having a memory effect such as Nitinol, are capable of self-expansion in the absence of a restoring force that holds the implant at a small diameter.
  • the restoring force is typically exerted on the material by a protective tube.
  • the implant in particular the stent, has a base body composed of an implant material.
  • An implant material is a nonliving material that is used for a medical application and interacts with biological systems.
  • a prerequisite for the use of a material as an implant material that is comes in contact with the physical surroundings when used as intended is its biocompatibility.
  • Biocompatibility refers to the capability of a material to evoke an appropriate tissue response in a specific application. This includes an adaptation of the chemical, physical, biological, and morphological surface properties of an implant to the recipient tissue, with the objective of achieving a clinically desired interaction.
  • the biocompatibility of the implant material is furthermore dependent on the time sequence of the response of the biosystem in which the implant is placed.
  • implant materials can be subdivided into bioactive, bioinert, and degradable/resorbable (referred to here as biocorrodible) materials.
  • Implant materials include polymers, metallic materials, and ceramic materials (as a coating, for example).
  • Biocompatible metals and metal alloys for permanent implants contain e.g. stainless steels (e.g. 316L), cobalt-based alloys (e.g. CoCrMo casting alloys, CoCrMo forging alloys, CoCrWNi forging alloys, and CoCrNiMo forging alloys), pure titanium and titanium alloys (e.g. CP titanium, TiAl6V4 or TiAl6Nb7), nickel-titanium alloys (e.g. NiTiNo1), and gold alloys.
  • the use of magnesium or pure iron and biocorrodible base alloys of the elements magnesium, iron, zinc, molybdenum, and tungsten is proposed.
  • implant materials with particularly tissue-compatible materials. These materials are usually organic or synthetic-polymeric in nature and are partially of natural origin. Further strategies for preventing restenosis focus on inhibiting proliferation using medication e.g. treatment using cytostatic agents.
  • the active agents can be provided e.g. on the implant surface in the form of a coating that releases an active agent.
  • the active agents are applied directly as a coating or are embedded in an elution matrix.
  • the elution matrix In the case of implants composed of biocorrodible materials in particular, it should also be possible for the elution matrix to be degraded in vivo.
  • the disadvantage of degradable and permanent polymers, which are typically used in active-agent-eluting implants as an elution matrix, is that they induce inflammatory responses at the implantation site over the long-term, thereby affecting the clinical result. A polymer-based elution matrix should therefore be eliminated if possible.
  • Implants without a polymer-based elution matrix are basically known from the prior art.
  • the substance which usually has an antiproliferative effect, can be applied in pure form or in a mixture with an excipient (auxiliary agent as the carrier) directly to the surface of the implant which can be smooth, roughened, or provided with structural recesses and which are used as a reservoir.
  • DAPT dual antiplatelet therapy
  • the implant comprises an active-agent-containing coating which covers the implant at least in sections.
  • the coating is composed of at least two subsections; a first subsection contains the at least one active substance, and a second subsection contains an auxiliary agent.
  • the invention is based on the finding that a polymeric elution matrix can be omitted if, instead, the active agent is applied in a structured manner, wherein the sections of the coating not coated with the active agent are covered by an auxiliary agent.
  • the sections of the implant surfaces covered by the auxiliary agent and the active agent therefore form a closed surface.
  • the auxiliary agent is designed such that it dissolves immediately after implantation.
  • the structured active-agent sections are exposed, and the surfaces of these sections can be enlarged greatly toward the surrounding medium, thereby also making it possible to improve an initial elution characteristic of the active agent.
  • the auxiliary agent is still present during implantation, thereby protecting the structure against wear and/or being washed away while it is being advanced toward the implantation site and while being secured, if applicable, at the implantation site.
  • a coating refers to the application, at least in sections, of the components of the coating on the base body of the implant.
  • the coating is preferably applied to the implant only abluminally.
  • a layer thickness is preferably in the range of 1 nm to 100 ⁇ m, and particularly preferably 300 nm to 15 ⁇ m.
  • the coating according to the invention can be applied directly to the implant surface, or additional intermediate layers can be provided; the base body of the implant may contain an inorganic base layer (e.g. sol-gel coatings) that improves the adhesion of the coating according to the invention. Additional layers can be applied to the coating according to the invention e.g. to simplify the introduction of the implant into the body.
  • the auxiliary agent can first be applied to the entire surface, and then this coating can be structured in the sense of the invention. The sections of the coating in which the auxiliary agent was removed in the structuring process are then filled with the active agent.
  • the structuring can take place e.g. by stamping, irradiation, or laser/temperature pressing.
  • the individual subsections are designed such that the result is a pattern of alternating strips of the first and the second subsections.
  • one width of the strips that form the first subsection of the coating is in the range of 1 to 30 ⁇ m.
  • the pattern can be regular in particular.
  • the stated dimension and pattern design has proven particularly effective for accelerating the adhesion behavior of a stent in the vascular wall.
  • the individual subsections are designed such that the result is a pattern of islands of the first subsection enclosed by the second subsection.
  • one width or one diameter of the islands that form the first subsection of the coating is in the range of 1 to 30 ⁇ m.
  • the pattern can be regular in particular.
  • the stated dimension and pattern design has proven particularly effective for accelerating the adhesion behavior of a stent in the vascular wall.
  • a base body of the implant is composed of a biocorrodible material, in particular a biocorrodible magnesium alloy.
  • those materials are referred to as being biocorrodible that degrade/convert in a physiological environment, and therefore the part of the implant composed of the material is then no longer present or at least substantially no longer present.
  • a magnesium alloy is understood to be a metallic microstructure having magnesium as the main component.
  • the main component is the alloy component that comprises the largest percentage by weight of the alloy.
  • a percentage of the main component is preferably more than 50% by weight, in particular more than 70% by weight.
  • the composition of the alloy should be selected such that the alloy is biocorrodible.
  • Artificial plasma as has been previously described according to EN ISO 10993-15:2000 for biocorrosion assays (composition NaCl 6.8 g/l, CaCl 2 0.2 g/l, KCl 0.4 g/l, MgSO 4 0.1 g/l, NaHCO 3 2.2 g/l, Na 2 HPO 4 0.126 g/l, NaH 2 PO 4 0.026 g/l), is used as a testing medium to test the corrosion behavior of an alloy under consideration. To perform the test, a sample of the alloy to be investigated is stored in a closed sample container with a defined quantity of the test medium at 37° C. and pH 7.38.
  • the artificial plasma according to EN ISO 10993-15:2000 corresponds to a medium similar to blood and thus represents a possibility for reproducibly simulating a physiological environment within the scope of the invention.
  • implants are devices introduced into the body using a surgical procedure, and comprise fastening elements for bone, such as screws, plates, or nails, surgical suture material, intestinal clamps, vascular clips, prostheses in the area of hard and soft tissue, and anchoring elements for electrodes, in particular of pacemakers or defibrillators.
  • the implant is composed entirely or in parts of the biocorrodible material.
  • the implant is preferably a stent,
  • the first subsection of the coating contains one or more active agents which are released after implantation.
  • an active agent is a medicinal agent having a pharmaceutical effect, and which is used in the human body or animal body to cure, alleviate, prevent, or detect illness.
  • Active agents include paclitaxel, sirolimus, and their derivatives in particular.
  • active agents are advantageous that act on mammalian target of rapamycin (mTOR), and rat sarcoma (RAS) inhibitors, in particular those that prevent RAS adhesion.
  • mTOR mammalian target of rapamycin
  • RAS rat sarcoma
  • the auxiliary agent can be dissolved completely in vivo in fewer than 10 h, in particular 2 h.
  • the auxiliary agent can consist of 80% or more by weight of a sugar or a sugar derivative.
  • a sugar or a sugar derivative for example, mixtures of 6-O- ⁇ -D-Glucopyranosyl-D-sorbitol (1,6-GPS) and 6-O- ⁇ -D-Glucopyranosyl-D-mannitol dihydrate (1,1-GPM) can be used.
  • Other possibilities include isomalt, lactose, cellulose powder, mannitol, calcium diphosphate, or sorbitol.
  • FIGS. 1A-D depict an overview of an exemplary method for manufacturing a coating for an implant and its state after implantation.
  • FIGS. 1A-1D The figure series is a schematic depiction of a way to manufacture the coating according to the invention.
  • FIGS. 1A-C show, in a highly schematized illustration of substeps A to C, one way to manufacture the coating according to the invention, and shows the state after implantation, in FIG. 1D .
  • the base body of implant 10 is coated with auxiliary agent 12 , thereby resulting in a closed surface.
  • substep B grooves are formed in this surface e.g. by stamping; the grooves are filled with the active agent in substep C, thereby resulting in a closed coating overall.
  • Auxiliary agent 12 is designed to dissolve quickly after implantation, thereby resulting in a structure after implantation that is similar to that shown in substep D in a highly schematicized manner.
  • a coating of the auxiliary agent is applied to a stent using an aerosol mist procedure.
  • the auxiliary agent is a 1:1 mixture of 6-O- ⁇ -D-Glucopyranosyl-D-sorbitol (1,6-GPS) and 6-O- ⁇ -D-Glucopyranosyl-D-mannitol dihydrate (1,1-GPM) which is dissolved in water for the aerosol mist procedure.
  • This auxiliary agent is available for galenical applications under the name GALENIQ oder Palatinit. It is easily structured under pressure and, unlike corn starch, dissolves easily in the bloodstream without complications.
  • the layer thickness in this case is 200 nm to 5 ⁇ m, preferably 1 to 3 ⁇ m.
  • Stamping is used to form grooves in the coating of auxiliary agent having a width of approximately 1-30 ⁇ m.
  • the grooves are filled with the active agent.
  • the following are used for this purpose: paclitaxel or rapamycin in combination with an excipient from the group iopromide (SeQuent Please), FreePac (Invatec), butyryl-n-trihexyl-citrate (BTHC) or triethyl citrate.
  • the auxiliary agent dissolves rapidly and the layer of active agent remains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention relates to an implant comprising an active-agent-containing coating which covers the implant at least in sections. The coating is composed of at least two subsections; a first subsection contains the at least one active substance, and a second subsection contains an auxiliary agent.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This invention claims benefit of priority to U.S. patent application Ser. No. 61/420,805, filed Dec. 8, 2010; the content of which is herein incorporated by reference in its entirety.
TECHNICAL FIELD
The invention relates to an implant comprising an active-agent-containing coating which covers the implant at least in sections.
BACKGROUND
Implants are utilized in modern medical technology in a variety of embodiments. They are used e.g. to support vessels, hollow organs, and ductal systems (endovascular implants e.g. stents), to attach and temporarily fix tissue implants and tissue transplants in position, and for orthopedic purposes such as pins, plates, or screws. The stent is a form of an implant that is used particularly frequently.
Stent implantation has become established as one of the most effective therapeutic measures for treating vascular disease. Stents are used to provide support in a patient's hollow organs. For this purpose, stents of a conventional design have a filigree support structure composed of metallic struts; the support structure is initially provided in a compressed form for insertion into the body, and is expanded at the application site. One of the main applications of stents of this type is to permanently or temporarily widen and hold open vasoconstrictions, in particular constrictions (stenoses) of the coronary arteries. In addition, aneurysm stents are known, for example, which are used primarily to seal the aneuryism. They also perform the support function.
Stents include a circumferential wall having a support force that suffices to hold the constricted vessel open to the desired extent; stents also include a tubular base body through which blood continues to flow without restriction. The circumferential wall is typically formed by a latticed support structure that enables the stent to be inserted, in a compressed state having a small outer diameter, until it reaches the constriction in the particular vessel to be treated, and to be expanded there, e.g. using a balloon catheter, until the vessel finally has the desired, enlarged inner diameter. Alternatively, materials having a memory effect, such as Nitinol, are capable of self-expansion in the absence of a restoring force that holds the implant at a small diameter. The restoring force is typically exerted on the material by a protective tube.
The implant, in particular the stent, has a base body composed of an implant material. An implant material is a nonliving material that is used for a medical application and interacts with biological systems. A prerequisite for the use of a material as an implant material that is comes in contact with the physical surroundings when used as intended is its biocompatibility. “Biocompatibility” refers to the capability of a material to evoke an appropriate tissue response in a specific application. This includes an adaptation of the chemical, physical, biological, and morphological surface properties of an implant to the recipient tissue, with the objective of achieving a clinically desired interaction. The biocompatibility of the implant material is furthermore dependent on the time sequence of the response of the biosystem in which the implant is placed. For example, irritations and inflammations, which can cause tissue changes, occur over the relative short term. Biological systems therefore respond differently depending on the properties of the implant material. Depending on the response of the biosystem, implant materials can be subdivided into bioactive, bioinert, and degradable/resorbable (referred to here as biocorrodible) materials.
Implant materials include polymers, metallic materials, and ceramic materials (as a coating, for example). Biocompatible metals and metal alloys for permanent implants contain e.g. stainless steels (e.g. 316L), cobalt-based alloys (e.g. CoCrMo casting alloys, CoCrMo forging alloys, CoCrWNi forging alloys, and CoCrNiMo forging alloys), pure titanium and titanium alloys (e.g. CP titanium, TiAl6V4 or TiAl6Nb7), nickel-titanium alloys (e.g. NiTiNo1), and gold alloys. In the field of biocorrodible stents, the use of magnesium or pure iron and biocorrodible base alloys of the elements magnesium, iron, zinc, molybdenum, and tungsten is proposed.
It is known that a greater level of biocompatibility can be achieved by coating implant materials with particularly tissue-compatible materials. These materials are usually organic or synthetic-polymeric in nature and are partially of natural origin. Further strategies for preventing restenosis focus on inhibiting proliferation using medication e.g. treatment using cytostatic agents. The active agents can be provided e.g. on the implant surface in the form of a coating that releases an active agent.
The active agents are applied directly as a coating or are embedded in an elution matrix. In the case of implants composed of biocorrodible materials in particular, it should also be possible for the elution matrix to be degraded in vivo. The disadvantage of degradable and permanent polymers, which are typically used in active-agent-eluting implants as an elution matrix, is that they induce inflammatory responses at the implantation site over the long-term, thereby affecting the clinical result. A polymer-based elution matrix should therefore be eliminated if possible.
Implants without a polymer-based elution matrix are basically known from the prior art. The substance, which usually has an antiproliferative effect, can be applied in pure form or in a mixture with an excipient (auxiliary agent as the carrier) directly to the surface of the implant which can be smooth, roughened, or provided with structural recesses and which are used as a reservoir.
Such implants have the disadvantage, however, that adhesion to the vascular wall is delayed, or occurs only partially or not at all over the long term. The risk therefore results e.g. of stent thrombosis occurring over the long term; to prevent this, systematic anticoagulation therapy is applied in clinical practice. This “dual antiplatelet therapy” (DAPT) has numerous clinical disadvantages that ultimately must be put up with in the form of delayed (or the absence of) adhesion of conventional implants.
SUMMARY
One or more of the aforementioned disadvantages of the prior art are overcome or at least diminished by the use of the implant according to the invention. The implant comprises an active-agent-containing coating which covers the implant at least in sections. The coating is composed of at least two subsections; a first subsection contains the at least one active substance, and a second subsection contains an auxiliary agent.
The invention is based on the finding that a polymeric elution matrix can be omitted if, instead, the active agent is applied in a structured manner, wherein the sections of the coating not coated with the active agent are covered by an auxiliary agent. The sections of the implant surfaces covered by the auxiliary agent and the active agent therefore form a closed surface. The auxiliary agent is designed such that it dissolves immediately after implantation. As a result, the structured active-agent sections are exposed, and the surfaces of these sections can be enlarged greatly toward the surrounding medium, thereby also making it possible to improve an initial elution characteristic of the active agent. However, the auxiliary agent is still present during implantation, thereby protecting the structure against wear and/or being washed away while it is being advanced toward the implantation site and while being secured, if applicable, at the implantation site.
According to the invention, a coating refers to the application, at least in sections, of the components of the coating on the base body of the implant. In the case of a stent, the coating is preferably applied to the implant only abluminally. A layer thickness is preferably in the range of 1 nm to 100 μm, and particularly preferably 300 nm to 15 μm. The coating according to the invention can be applied directly to the implant surface, or additional intermediate layers can be provided; the base body of the implant may contain an inorganic base layer (e.g. sol-gel coatings) that improves the adhesion of the coating according to the invention. Additional layers can be applied to the coating according to the invention e.g. to simplify the introduction of the implant into the body. Methods for coating implants are known to a person skilled in the art (e.g. pipetting, rolling). To make the coating according to the invention, the auxiliary agent can first be applied to the entire surface, and then this coating can be structured in the sense of the invention. The sections of the coating in which the auxiliary agent was removed in the structuring process are then filled with the active agent. The structuring can take place e.g. by stamping, irradiation, or laser/temperature pressing.
According to a first, preferred embodiment, the individual subsections are designed such that the result is a pattern of alternating strips of the first and the second subsections. In particular, one width of the strips that form the first subsection of the coating is in the range of 1 to 30 μm. The pattern can be regular in particular. The stated dimension and pattern design has proven particularly effective for accelerating the adhesion behavior of a stent in the vascular wall.
According to a second, preferred embodiment, the individual subsections are designed such that the result is a pattern of islands of the first subsection enclosed by the second subsection. In particular, one width or one diameter of the islands that form the first subsection of the coating is in the range of 1 to 30 μm. The pattern can be regular in particular. The stated dimension and pattern design has proven particularly effective for accelerating the adhesion behavior of a stent in the vascular wall.
Preferably, a base body of the implant is composed of a biocorrodible material, in particular a biocorrodible magnesium alloy.
Within the scope of the invention, those materials are referred to as being biocorrodible that degrade/convert in a physiological environment, and therefore the part of the implant composed of the material is then no longer present or at least substantially no longer present.
In this context, a magnesium alloy is understood to be a metallic microstructure having magnesium as the main component. The main component is the alloy component that comprises the largest percentage by weight of the alloy. A percentage of the main component is preferably more than 50% by weight, in particular more than 70% by weight. The composition of the alloy should be selected such that the alloy is biocorrodible.
Artificial plasma, as has been previously described according to EN ISO 10993-15:2000 for biocorrosion assays (composition NaCl 6.8 g/l, CaCl2 0.2 g/l, KCl 0.4 g/l, MgSO4 0.1 g/l, NaHCO3 2.2 g/l, Na2HPO4 0.126 g/l, NaH2PO4 0.026 g/l), is used as a testing medium to test the corrosion behavior of an alloy under consideration. To perform the test, a sample of the alloy to be investigated is stored in a closed sample container with a defined quantity of the test medium at 37° C. and pH 7.38. At time intervals defined according to the anticipated corrosion behavior, of a few hours up to multiple months, the samples are removed and examined in a known manner for traces of corrosion. The artificial plasma according to EN ISO 10993-15:2000 corresponds to a medium similar to blood and thus represents a possibility for reproducibly simulating a physiological environment within the scope of the invention.
Within the scope of the invention, implants are devices introduced into the body using a surgical procedure, and comprise fastening elements for bone, such as screws, plates, or nails, surgical suture material, intestinal clamps, vascular clips, prostheses in the area of hard and soft tissue, and anchoring elements for electrodes, in particular of pacemakers or defibrillators. The implant is composed entirely or in parts of the biocorrodible material. The implant is preferably a stent,
The first subsection of the coating contains one or more active agents which are released after implantation. According to the invention, an active agent is a medicinal agent having a pharmaceutical effect, and which is used in the human body or animal body to cure, alleviate, prevent, or detect illness. Active agents include paclitaxel, sirolimus, and their derivatives in particular. In particular, active agents are advantageous that act on mammalian target of rapamycin (mTOR), and rat sarcoma (RAS) inhibitors, in particular those that prevent RAS adhesion.
Preferably, the auxiliary agent can be dissolved completely in vivo in fewer than 10 h, in particular 2 h. The auxiliary agent can consist of 80% or more by weight of a sugar or a sugar derivative. For example, mixtures of 6-O-α-D-Glucopyranosyl-D-sorbitol (1,6-GPS) and 6-O-α-D-Glucopyranosyl-D-mannitol dihydrate (1,1-GPM) can be used. Other possibilities include isomalt, lactose, cellulose powder, mannitol, calcium diphosphate, or sorbitol.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A-D depict an overview of an exemplary method for manufacturing a coating for an implant and its state after implantation.
 DETAILED DESCRIPTION
The invention is explained in greater detail in the following with reference to an embodiment and FIGS. 1A-1D. The figure series is a schematic depiction of a way to manufacture the coating according to the invention.
FIGS. 1A-C show, in a highly schematized illustration of substeps A to C, one way to manufacture the coating according to the invention, and shows the state after implantation, in FIG. 1D. In substep A, the base body of implant 10 is coated with auxiliary agent 12, thereby resulting in a closed surface. In substep B, grooves are formed in this surface e.g. by stamping; the grooves are filled with the active agent in substep C, thereby resulting in a closed coating overall. Auxiliary agent 12 is designed to dissolve quickly after implantation, thereby resulting in a structure after implantation that is similar to that shown in substep D in a highly schematicized manner.
Embodiment
A coating of the auxiliary agent is applied to a stent using an aerosol mist procedure. The auxiliary agent is a 1:1 mixture of 6-O-α-D-Glucopyranosyl-D-sorbitol (1,6-GPS) and 6-O-α-D-Glucopyranosyl-D-mannitol dihydrate (1,1-GPM) which is dissolved in water for the aerosol mist procedure. This auxiliary agent is available for galenical applications under the name GALENIQ oder Palatinit. It is easily structured under pressure and, unlike corn starch, dissolves easily in the bloodstream without complications. The layer thickness in this case is 200 nm to 5 μm, preferably 1 to 3 μm. Stamping is used to form grooves in the coating of auxiliary agent having a width of approximately 1-30 μm. Next, the grooves are filled with the active agent. The following are used for this purpose: paclitaxel or rapamycin in combination with an excipient from the group iopromide (SeQuent Please), FreePac (Invatec), butyryl-n-trihexyl-citrate (BTHC) or triethyl citrate. After implantation, the auxiliary agent dissolves rapidly and the layer of active agent remains.
It will be apparent to those skilled in the art that numerous modifications and variations of the described examples and embodiments are possible in light of the above teaching. The disclosed examples and embodiments are presented for purposes of illustration only. Therefore, it is the intent to cover all such modifications and alternate embodiments as may come within the true scope of this invention.

Claims (16)

What is claimed is:
1. An implant comprising a base body and a coating which covers the base body, the coating comprising least two adjacent subsections; a first subsection containing at least one active agent, and a second subsection containing an auxiliary agent, wherein at least one of the subsections is a polymer free section, further wherein the first subsection fills grooves in the second subsection thereby remaining partially uncovered and the second subsection is configured to dissolve after implantation thereby increasing exposure of the first subsection to a surrounding medium.
2. The implant according to claim 1, wherein the individual subsections are designed such that the result is a pattern of alternating strips of the first and the second subsections.
3. The implant according to claim 2, wherein one width of the strips that form the first subsection of the coating is in the range of 1 to 30 μm.
4. The implant according to claim 2, wherein the pattern repeats.
5. The implant according to claim 1, wherein the individual subsections are designed such that the result is a pattern of islands of the first subsection enclosed by the second subsection.
6. The implant according to claim 5, wherein one width or one diameter of the islands that form the first subsection of the coating is in the range of 1 to 30 μm.
7. The implant according to claim 1, wherein the base body of the implant is composed of a biocorrodible material.
8. The implant according to claim 7, wherein the base body is composed of a biocorrodible magnesium alloy.
9. The implant according to claim 1, wherein the active agent is selected from the group consisting of paclitaxel, sirolimus, a derivative of sirolimus, and one or more RAS inhibitors.
10. The implant according to claim 1, wherein the auxiliary agent dissolves completely in vivo in fewer than 10 h.
11. The implant according to claim 10, wherein the auxiliary agent comprises 80% or more by weight of a sugar or a sugar derivative.
12. The implant according to claim 1, wherein the implant is a stent.
13. The implant according to claim 1, wherein the first subsection is the polymer free section.
14. The implant according to claim 1, wherein the second subsection is the polymer free section.
15. The implant according to claim 1, wherein both the first and second subsections are polymer free.
16. The implant according to claim 1, wherein both the first and second subsections form a closed coating preventing access to the base body.
US13/306,238 2010-12-08 2011-11-29 Implant comprising an active-agent-containing coating covering the implant at least in sections Active 2033-06-12 US9452243B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/306,238 US9452243B2 (en) 2010-12-08 2011-11-29 Implant comprising an active-agent-containing coating covering the implant at least in sections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42080510P 2010-12-08 2010-12-08
US13/306,238 US9452243B2 (en) 2010-12-08 2011-11-29 Implant comprising an active-agent-containing coating covering the implant at least in sections

Publications (2)

Publication Number Publication Date
US20120150284A1 US20120150284A1 (en) 2012-06-14
US9452243B2 true US9452243B2 (en) 2016-09-27

Family

ID=45217237

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/306,238 Active 2033-06-12 US9452243B2 (en) 2010-12-08 2011-11-29 Implant comprising an active-agent-containing coating covering the implant at least in sections

Country Status (2)

Country Link
US (1) US9452243B2 (en)
EP (1) EP2462962B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11890004B2 (en) 2021-05-10 2024-02-06 Cilag Gmbh International Staple cartridge comprising lubricated staples

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017727B1 (en) * 2017-02-24 2022-12-06 Qvanteq Ag IMPLANT FOR INSERTION INTO A BODY LUMEN, METHOD FOR MANUFACTURING THE SAME AND IMPLANT SET
CN112930202B (en) * 2018-08-24 2023-10-27 扩凡科技有限公司 Vascular device and method for producing a vascular device
KR20210143817A (en) * 2019-03-19 2021-11-29 크판테크 아게 Medical devices and processes for manufacturing medical devices

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034409A1 (en) * 2002-08-13 2004-02-19 Biotronik Mess-Und Therapiegeraete Gmbh & Co. Stent with polymeric coating
US20060155370A1 (en) * 2002-10-22 2006-07-13 Medtronic Vascular, Inc. Stent with intermittent coating
US20070207186A1 (en) * 2006-03-04 2007-09-06 Scanlon John J Tear and abrasion resistant expanded material and reinforcement
US20070244548A1 (en) 2006-02-27 2007-10-18 Cook Incorporated Sugar-and drug-coated medical device
US20080082162A1 (en) * 2006-09-15 2008-04-03 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20090024200A1 (en) 2007-07-20 2009-01-22 Medtronic Vascular, Inc. Drug Eluting Medical Device and Method
EP2070558A2 (en) 2007-12-10 2009-06-17 BIOTRONIK VI Patent AG Implants with membrane diffusion controlled active ingredient release

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034409A1 (en) * 2002-08-13 2004-02-19 Biotronik Mess-Und Therapiegeraete Gmbh & Co. Stent with polymeric coating
US20060155370A1 (en) * 2002-10-22 2006-07-13 Medtronic Vascular, Inc. Stent with intermittent coating
US20070244548A1 (en) 2006-02-27 2007-10-18 Cook Incorporated Sugar-and drug-coated medical device
US20070207186A1 (en) * 2006-03-04 2007-09-06 Scanlon John J Tear and abrasion resistant expanded material and reinforcement
US20080082162A1 (en) * 2006-09-15 2008-04-03 Boston Scientific Scimed, Inc. Bioerodible endoprostheses and methods of making the same
US20090024200A1 (en) 2007-07-20 2009-01-22 Medtronic Vascular, Inc. Drug Eluting Medical Device and Method
EP2070558A2 (en) 2007-12-10 2009-06-17 BIOTRONIK VI Patent AG Implants with membrane diffusion controlled active ingredient release
US8257729B2 (en) 2007-12-10 2012-09-04 Biotronik Vi Patent Ag Implants with membrane diffusion-controlled release of active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EP11189695.7 European Search Report mailed Aug. 28, 2014.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11890004B2 (en) 2021-05-10 2024-02-06 Cilag Gmbh International Staple cartridge comprising lubricated staples
US11998192B2 (en) 2021-05-10 2024-06-04 Cilag Gmbh International Adaptive control of surgical stapling instrument based on staple cartridge type

Also Published As

Publication number Publication date
US20120150284A1 (en) 2012-06-14
EP2462962A3 (en) 2014-10-01
EP2462962B1 (en) 2017-09-20
EP2462962A2 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
Heiden et al. Magnesium, iron and zinc alloys, the trifecta of bioresorbable orthopaedic and vascular implantation-a review
Mani et al. Coronary stents: a materials perspective
US8992600B2 (en) Marker composite and medical implant comprising an X-ray marker
US20090024211A1 (en) Stent with a coating or filling of a cavity
US20090018648A1 (en) Stent with a coating
US20080051872A1 (en) Biocorrodible metallic implant having a coating or cavity filling made of a peg/plga copolymer
US9254350B2 (en) Implantable medical devices having bioabsorbable primer polymer coatings
US20100023112A1 (en) Biocorrodible implant with a coating comprising a hydrogel
US9017398B2 (en) Abluminally coated drug-eluting stents having a form-fitting protective layer
JP2006500996A (en) Apparatus and method for delivering mitomycin via an eluting biocompatible implantable medical device
Wang et al. In vitro and in vivo assessment of the biocompatibility of an paclitaxel-eluting poly-l-lactide-coated Mg-Zn-Y-Nd alloy stent in the intestine
US9452243B2 (en) Implant comprising an active-agent-containing coating covering the implant at least in sections
US10512712B2 (en) Polylactide-coated implant composed of a biocorrodible magnesium alloy
US20120150282A1 (en) Implant having a paclitaxel-releasing coating
JP7531480B2 (en) Improving polymer layers on degradable devices
US20090112307A1 (en) Stent having a base body of a bioinert metallic implant material
ES2640274T3 (en) Implant of a biocorrosible magnesium alloy
US20120239140A1 (en) Medical product comprising an active coating
WO2022061430A1 (en) Non-polymeric cylindrical tubular prosthetic device
US8852622B2 (en) Coated implant composed of a biocorrodible magnesium alloy
US10016775B2 (en) Device for coating a stent and associated coating method and stent produced according to the method
US20120150281A1 (en) Implant made of biocorrodible material and with a coating containing a tissue adhesive
US20110034990A1 (en) Biocorrodible implant with active coating
Kathuria Some aspects of drug eluting stents
Rastogi et al. Drug eluting stents and beyond

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOTRONIK AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRATZ, MATTHIAS, DR.;BORCK, ALEXANDER, DR.;RZANY, ALEXANDER, DR.;AND OTHERS;SIGNING DATES FROM 20111110 TO 20111117;REEL/FRAME:027297/0156

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载